Follow
Erik M Volz
Title
Cited by
Cited by
Year
Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand
N Ferguson, D Laydon, G Nedjati Gilani, N Imai, K Ainslie, M Baguelin, ...
43292020
Estimates of the severity of coronavirus disease 2019: a model-based analysis
R Verity, LC Okell, I Dorigatti, P Winskill, C Whittaker, N Imai, ...
The Lancet infectious diseases 20 (6), 669-677, 2020
38762020
Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity
E Volz, V Hill, JT McCrone, A Price, D Jorgensen, O’Toole, J Southgate, ...
Cell 184 (1), 64-75. e11, 2021
8862021
Assessing transmissibility of SARS-CoV-2 lineage B. 1.1. 7 in England
E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ...
Nature 593 (7858), 266-269, 2021
8262021
Report 13: Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries
S Flaxman, S Mishra, A Gandy, H Unwin, H Coupland, T Mellan, H Zhu, ...
7652020
Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations
A Rambaut, N Loman, O Pybus, W Barclay, J Barrett, A Carabelli, ...
Genom. Epidemiol, 1-5, 2020
7222020
Probability based estimation theory for respondent driven sampling
E Volz, DD Heckathorn
Journal of official statistics 24 (1), 79, 2008
6882008
Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data
E Volz, S Mishra, M Chand, JC Barrett, R Johnson, L Geidelberg, ...
MedRxiv, 2020.12. 30.20249034, 2021
5712021
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
KA Twohig, T Nyberg, A Zaidi, S Thelwall, MA Sinnathamby, S Aliabadi, ...
The Lancet Infectious Diseases 22 (1), 35-42, 2022
5322022
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study
T Nyberg, NM Ferguson, SG Nash, HH Webster, S Flaxman, N Andrews, ...
The Lancet 399 (10332), 1303-1312, 2022
5142022
Viral phylodynamics
EM Volz, K Koelle, T Bedford
PLoS computational biology 9 (3), e1002947, 2013
3942013
SIR dynamics in random networks with heterogeneous connectivity
E Volz
Journal of mathematical biology 56, 293-310, 2008
3842008
Reduction in mobility and COVID-19 transmission
P Nouvellet, S Bhatia, A Cori, KEC Ainslie, M Baguelin, S Bhatt, ...
Nature communications 12 (1), 1090, 2021
3622021
Susceptible–infected–recovered epidemics in dynamic contact networks
E Volz, LA Meyers
Proceedings of the Royal Society B: Biological Sciences 274 (1628), 2925-2934, 2007
3312007
Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B. 1.1. 7
B Meng, SA Kemp, G Papa, R Datir, IATM Ferreira, S Marelli, WT Harvey, ...
Cell reports 35 (13), 2021
2922021
Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK
L Du Plessis, JT McCrone, AE Zarebski, V Hill, C Ruis, B Gutierrez, ...
Science 371 (6530), 708-712, 2021
2902021
Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B. 1.1. 7: an ecological study
MS Graham, CH Sudre, A May, M Antonelli, B Murray, T Varsavsky, ...
The Lancet Public Health 6 (5), e335-e345, 2021
2772021
Edge-based compartmental modelling for infectious disease spread
JC Miller, AC Slim, EM Volz
Journal of the Royal Society Interface 9 (70), 890-906, 2012
2592012
Phylodynamics of infectious disease epidemics
EM Volz, SL Kosakovsky Pond, MJ Ward, AJ Leigh Brown, SDW Frost
Genetics 183 (4), 1421-1430, 2009
2512009
Phylodynamics of infectious disease epidemics
EM Volz, SL Kosakovsky Pond, MJ Ward, AJ Leigh Brown, SDW Frost
Genetics 183 (4), 1421-1430, 2009
2512009
The system can't perform the operation now. Try again later.
Articles 1–20